poisar

Stock

Neurocrine Biosciences, Inc. NBIX

$150.82-3.62%

Overview

NBIX market data

Price History

NBIX price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
23.56
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$4.67
Diluted earnings per share over the trailing twelve months.
Beta
0.40
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
20.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$122.14 – $186.12
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $16.6B · P/B 4.35 · P/S 4.93.

Company News

10 captured
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182Benzinga · Aug 13, 2026, 2:43 PM
What's Going On With Neurocrine Biosciences Stock On Wednesday?Benzinga · Aug 12, 2026, 3:57 PM
Neurocrine Biosciences Announces Publication Of Its KINCET-PRO Phase 4 Study Results Showing That Once-Daily INGREZZA Capsules Led To Substantial And Sustained Improvements In Patient-Reported Quality Of Life And FunctionalityBenzinga · Aug 12, 2026, 12:37 PM
Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For ObesityBenzinga · Aug 7, 2026, 12:33 PM
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026Globenewswire Inc · Aug 7, 2026, 11:00 AM
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210Benzinga · Aug 3, 2026, 9:25 PM
Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213Benzinga · Aug 3, 2026, 2:06 PM
Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194Benzinga · Aug 3, 2026, 1:08 PM
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $249Benzinga · Jul 31, 2026, 8:54 PM
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198Benzinga · Jul 31, 2026, 7:23 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock